Specialty Pharma Journal Specialty, Precision & Technology
KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, …
Read More »FDA Grants Orphan Drug Designation to Lynparza for Treatment of Pancreatic Cancer
Recent Posts
Cannabics Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome
TEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2018 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: …
Read More »Scripps Research Translational Institute Collaborates with Seqster To Bring Genetic Risk Scores With Health Data
SAN DIEGO, Oct. 16, 2018 /PRNewswire/ — Seqster, the leading consumer-centric health data management platform …
Read More »Gottlieb Makes Statement on FDA’s New Steps to Modernize Drug Development, Improve Efficiency and Promote Innovation of Targeted Therapies
The FDA continues to advance new policies, modernize our programs and advance opportunities for developing more targeted …
Read More »Alnylam to Initiate Rolling Submission of NDA and Pursue Full Approval for Givosiran for Acute Hepatic Porphyria
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that in …
Read More »Genentech’s Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …
Read More »FDA Grants Breakthrough Therapy Designation to Loxo Oncology’s Investigational LOXO-292 for RET Fusion-Positive Thyroid Cancer
STAMFORD, Conn., Oct. 15, 2018 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines …
Read More »Bristol-Myers Squibb’s Opdivo Fails to Meet Primary Endpoint in Phase 3 Study in Patients with Relapsed Small Cell Lung Cancer
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 …
Read More »Bristol-Myers Squibb and Compugen Partner to Evaluate Therapeutic Regimen in Advanced Solid Tumors
NEW YORK & HOLON, Israel–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies …
Read More »FDA Grants Orphan Drug Designation to Synspira’s Investigational Cystic Fibrosis Therapy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Synspira, a privately held company developing a new class of inhaled glycopolymer-based therapeutics …
Read More »FDA Approves Stiolto Respimat sNDA to Add on COPD Exacerbation Reduction
RIDGEFIELD, Conn., Oct. 11, 2018 /PRNewswire/ — Boehringer Ingelheim announced today that the U.S. Food …
Read More »Recent Survey Reveals that Multiple Sclerosis Patients Want More Information on Brain Atrophy
SUMMIT, N.J.–(BUSINESS WIRE)–A new survey examines the topic of brain volume loss, known as brain …
Read More »FDA Lifts Clinical Hold on Vertex/CRISPR Therapeutics’ Investigational Gene Therapy CTX001 for the Treatment of Sickle Cell Disease
ZUG, Switzerland and BOSTON and CAMBRIDGE, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative …
Read More »Celltrion and Teva Announce FDA Advisory Committee Recommends Approval of CT-P10, a Proposed Rituximab Biosimilar
SILVER SPRING, Md. & JERUSALEM–(BUSINESS WIRE)– Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and …
Read More »Teva Presents 25-Year Safety Data from Longest Continuous Trial of Copaxone for Treatment of Relapsing Forms of Multiple Sclerosis
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced safety and tolerability results …
Read More »